Pamela Shaw

Pamela Shaw

Auto-generated profile, based on publicly available information

Pamela Shaw

Galter Health Sciences Library, Feinberg School of Medicine, Northwestern University, Chicago, Illinois

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2002 in Neuroscience
Verified
Journal Article
Closed access
MMM.-M Mesulam
M.-M Mesulam
AGA Guillozet
A Guillozet
PSP Shaw
P Shaw
ALA Levey
A Levey
EDE.G Duysen
E.G Duysen
OLO Lockridge
O Lockridge

1 March 2007 in Neurobiology of Aging
Verified
Journal Article
Closed access
AGAneta Grudzien
Aneta Grudzien
PSPamela Shaw
Pamela Shaw
SWSandra Weintraub
Sandra Weintraub
EBEileen Bigio
Eileen Bigio
DMDeborah C. Mash
Deborah C. Mash
MMM. Marsel Mesulam
M. Marsel Mesulam

27 May 2004 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
MMMarsel Mesulam
Marsel Mesulam
PSPamela Shaw
Pamela Shaw
DMDeborah Mash
Deborah Mash
SWSandra Weintraub
Sandra Weintraub

1 February 2002 in Neurobiology of Disease
Verified
Journal Article
Closed access
MMMarsel Mesulama
Marsel Mesulama
AGAngela Guillozetb
Angela Guillozetb
PSPamela Shawb
Pamela Shawb
BQBruce Quinnc
Bruce Quinnc

21 August 2006 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
MLMary P. Lambert
Mary P. Lambert
PVPauline T. Velasco
Pauline T. Velasco
LCLei Chang
Lei Chang
KVKirsten L. Viola
Kirsten L. Viola
SFSara Fernandez
Sara Fernandez
WKWilliam L Klein
William L Klein
Amyloid beta (Aβ) immunotherapy for Alzheimer's disease has shown initial success in mouse models of Alzheimer's disease and in human patients. However, because of meningoencephalitis in clinical trials of active vaccination, approaches using therapeutic antibodies may be preferred. As a novel antigen to generate monoclonal antibodies, the current study has used Aβ oligomers (amyloid β‐derived diffusible ligands, ADDLs), pathological assemblies known to accumulate in Alzheimer's disease brain. Clones were selected for the ability to discriminate Alzheimer's disease from control brains in extracts and tissue sections. These antibodies recognized Aβ oligomers and fibrils but not the physiologically prevalent Aβ monomer. Discrimination derived from an epitope found in assemblies of Aβ1–28 and ADDLs but not in other sequences, including Aβ1–40. Immunoneutralization experiments showed that toxicity and attachment of ADDLs to synapses in culture could be prevented. ADDL‐induced reactive oxygen species (ROS) generation was also inhibited, establishing this response to be oligomer‐dependent. Inhibition occurred whether ADDLs were prepared in vitro or obtained from Alzheimer's disease brain. As conformationally sensitive monoclonal antibodies that selectively immunoneutralize binding and function of pathological Aβ assemblies, these antibodies provide tools by which pathological Aβ assemblies from Alzheimer's disease brain might be isolated and evaluated, as well as offering a valuable prototype for new antibodies useful for Alzheimer's disease therapeutics.

2 February 2017 in Journal of Clinical and Translational Science
Verified
Journal Article
Open access
PDF file
DFDaniel G. Fort
Daniel G. Fort
THTimothy M. Herr
Timothy M. Herr
PSPamela L. Shaw
Pamela L. Shaw
KGKaren E. Gutzman
Karen E. Gutzman
JSJustin B. Starren
Justin B. Starren
Objective: Systematic review and analysis of definitions of translational research.Materials and methods: The final corpus was comprised of 33 papers, each read by at least 2 reviewers. Definitions were mapped to a common set of research processes for presentation and analysis. Influence of papers and definitions was further evaluated using citation analysis and agglomerative clustering.Results: All definitions were mapped to common research processes, revealing most common labels for each process. Agglomerative clustering revealed 3 broad families of definitions. Citation analysis showed that the originating paper of each family has been cited ~10 times more than any other member.Discussion: Although there is little agreement between definitions, we were able to identify an emerging consensus 5-phase (T0–T4) definition for translational research. T1 involves processes that bring ideas from basic research through early testing in humans. T2 involves the establishment of effectiveness in humans and clinical guidelines. T3 primarily focuses on implementation and dissemination research while T4 focuses on outcomes and effectiveness in populations. T0 involves research such as genome-wide association studies which wrap back around to basic research.Conclusion: We used systematic review and analysis to identify emerging consensus between definitions of translational research phases.